Laurence Amar

List of Publications by Year
in descending order

149 papers	14,276 citations	26630 56 h-index	20358 116 g-index
161 all docs	161 docs citations	161 times ranked	9901 citing authors

#	Article	IF	Citations
1	Genetic Testing in Pheochromocytoma or Functional Paraganglioma. Journal of Clinical Oncology, 2005, 23, 8812-8818.	1.6	612
2	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
3	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
4	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
5	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
6	An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology, The, 2009, 10, 764-771.	10.7	477
7	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	21.4	460
8	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet, The, 2015, 385, 1957-1965.	13.7	453
9	Cardiovascular Complications Associated With Primary Aldosteronism. Hypertension, 2013, 62, 331-336.	2.7	402
10	Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3822-3828.	3.6	399
11	Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology, 2015, 11, 101-111.	9.6	396
12	The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2817-2827.	3.6	353
13	European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. European Journal of Endocrinology, 2016, 174, G1-G10.	3.7	352
14	Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2110-2116.	3.6	324
15	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics, 2014, 23, 2440-2446.	2.9	316
16	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	3.6	310
17	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
18	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics, 2011, 20, 3974-3985.	2.9	266

#	Article	IF	Citations
19	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
20	Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
21	The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLoS ONE, 2009, 4, e7094.	2.5	203
22	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.5	190
23	KCNJ5 Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	2.7	176
24	Aldosterone Synthase Inhibition With LCI699. Hypertension, 2010, 56, 831-838.	2.7	161
25	WNT/Î²-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Human Molecular Genetics, 2014, 23, 889-905.	2.9	157
26	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	5.1	155
27	A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nature Genetics, 2018, 50, 355-361.	21.4	154
28	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
29	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
30	A Clinical Prediction Score to Diagnose Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3530-3537.	3.6	148
31	Adherence to Antihypertensive Treatment and the Blood Pressureâ€“Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation, 2016, 134, 847-857.	1.6	144
32	Imaging Work-Up for Screening of Paraganglioma and Pheochromocytoma inSDHxMutation Carriers: A Multicenter Prospective Study from the PGL.EVA Investigators. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E162-E173.	3.6	130
33	Adrenal Cortex Remodeling and Functional Zona Glomerulosa Hyperplasia in Primary Aldosteronism. Hypertension, 2010, 56, 885-892.	2.7	128
34	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics, 2012, 21, 5397-5405.	2.9	126
35	CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism. EBioMedicine, 2016, 13, 225-236.	6.1	119
36	Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. Journal of Hypertension, 2008, 26, 1816-1823.	0.5	117

#	Article	IF	Citations
37	High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia. Hypertension, 2017, 70, 652-658.	2.7	115
38	Fasting Plasma Glucose and Serum Lipids in Patients With Primary Aldosteronism. Hypertension, 2009, 53, 605-610.	2.7	111
39	Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrology Dialysis Transplantation, 2004, 19, 774-777.	0.7	109
40	Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart, 2013, 99, 1438-1444.	2.9	105
41	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	3.6	103
42	Outcomes of Adrenalectomy in Patients with Unilateral Primary Aldosteronism: A Review. Hormone and Metabolic Research, 2012, 44, 221-227.	1.5	102
43	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4006-4012.	3.6	102
44	Inactivation of theAPCGene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. Clinical Cancer Research, 2010, 16, 5133-5141.	7.0	97
45	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	2.7	97
46	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. Cancer Research, 2018, 78, 1914-1922.	0.9	96
47	Genetic, Cellular, and Molecular Heterogeneity in Adrenals With Aldosterone-Producing Adenoma. Hypertension, 2020, 75, 1034-1044.	2.7	89
48	Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E954-E962.	3.6	87
49	Aldosterone-Producing Adenoma Formation in the Adrenal Cortex Involves Expression of Stem/Progenitor Cell Markers. Endocrinology, 2011, 152, 4753-4763.	2.8	85
50	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1109-1118.	3.6	82
51	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2019, 25, 760-770.	7.0	82
52	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	9.6	80
53	Aldosterone synthase inhibition in humans. Nephrology Dialysis Transplantation, 2013, 28, 36-43.	0.7	79
54	Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2012, 23, 34-42.	9.0	75

#	Article	IF	Citations
55	Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2012, 44, 385-389.	1.5	66
56	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	3.6	65
57	Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet Journal of Rare Diseases, 2010, 5, 9.	2.7	60
58	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. Journal of Medical Genetics, 2019, 56, 513-520.	3.2	60
59	Hereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency. Hormone Research in Paediatrics, 2005, 63, 171-179.	1.8	57
60	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	7.1	57
61	RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 376-379.	1.9	55
62	Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma. Hypertension, 2015, 66, 1014-1022.	2.7	55
63	In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. Clinical Cancer Research, 2016, 22, 1120-1129.	7.0	54
64	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	10.0	54
65	MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. European Journal of Endocrinology, 2016, 175, R135-R145.	3.7	52
66	SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. Annales D'Endocrinologie, 2016, 77, 179-186.	1.4	50
67	Influence of Diagnostic Criteria on the Interpretation of Adrenal Vein Sampling. Hypertension, 2015, 65, 849-854.	2.7	48
68	SDHD Immunohistochemistry: A New Tool to ValidateSDHxMutations in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E287-E291.	3.6	45
69	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
70	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	3.6	44
71	Primary aldosteronism and pregnancy. Annales D'Endocrinologie, 2016, 77, 148-160.	1.4	43
72	KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Molecular and Cellular Endocrinology, 2013, 371, 221-227.	3.2	38

#	Article	IF	Citations
73	Risk assessment of maternally inheritedSDHDparaganglioma and phaeochromocytoma. Journal of Medical Genetics, 2017, 54, 125-133.	3.2	37
74	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nature Genetics, 2021, 53, 1360-1372.	21.4	37
75	Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. Clinical Endocrinology, 2015, 83, 298-302.	2.4	35
76	SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing. Annales D'Endocrinologie, 2016, 77, 202-207.	1.4	34
77	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	12.8	34
78	Peritoneal Implantation of Pheochromocytoma Following Tumor Capsule Rupture During Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2681-E2685.	3.6	33
79	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)â€"clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	3.8	33
80	Mast Cell Hyperplasia Is Associated With Aldosterone Hypersecretion in a Subset of Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E550-E560.	3.6	32
81	Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. Journal of Hypertension, 2013, 31, 624-629.	0.5	31
82	Cause of renal infarction. Journal of Hypertension, 2018, 36, 634-640.	0.5	31
83	LB01.11. Journal of Hypertension, 2015, 33, e47.	0.5	28
84	Ectopic Hormoneâ€Secreting Pheochromocytoma: A Francophone Observational Study. World Journal of Surgery, 2012, 36, 1382-1388.	1.6	27
85	Video-assisted thoracoscopic surgery as a first-line treatment for mediastinal parathyroid adenomas: strategic value of imaging. European Journal of Endocrinology, 2004, 150, 141-147.	3.7	26
86	Changes in Urinary Total Metanephrine Excretion in Recurrent and Malignant Pheochromocytomas and Secreting Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 383-391.	3.8	26
87	Macrolides for KCNJ5â€"mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism. Blood Pressure, 2018, 27, 200-205.	1.5	25
88	Criteria for diagnosing primary aldosteronism on the basis of liquid chromatographyâ€"tandem mass spectrometry determinations of plasma aldosterone concentration. Journal of Hypertension, 2018, 36, 1592-1601.	0.5	24
89	Functional histopathological markers of aldosterone producing adenoma and somatic KCNJ5 mutations. Molecular and Cellular Endocrinology, 2015, 408, 220-226.	3.2	23
90	Suppression of Aldosterone Secretion After Recumbent Saline Infusion Does Not Exclude Lateralized Primary Aldosteronism. Hypertension, 2016, 68, 989-994.	2.7	23

#	Article	IF	Citations
91	SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery. Annales D'Endocrinologie, 2016, 77, 220-225.	1.4	23
92	Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans. JACC: Cardiovascular Imaging, 2020, 13, 2149-2159.	5.3	23
93	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1510-1517.	6.4	22
94	Phaeochromocytomas and functional paragangliomas: Clinical management. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 933-941.	4.7	19
95	Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor. European Journal of Endocrinology, 2012, 166, 131-135.	3.7	19
96	Outcomes of Drug-Based and Surgical Treatments for Primary Aldosteronism. Advances in Chronic Kidney Disease, 2015, 22, 196-203.	1.4	19
97	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
98	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
99	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	3.6	18
100	Primary stenting for atherosclerotic renal artery stenosis. Journal of Vascular Surgery, 2010, 51, 1574-1580.e1.	1.1	17
101	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
102	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4764-4768.	3.6	16
103	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 519-530.	3.1	16
104	PROGRESS IN PRIMARY ALDOSTERONISM: Mineralocorticoid antagonist treatment for aldosterone-producing adenoma. European Journal of Endocrinology, 2015, 172, R125-R129.	3.7	14
105	Sex differences in antihypertensive treatment in France among 17â€Š856 patients in a tertiary hypertension unit. Journal of Hypertension, 2018, 36, 939-946.	0.5	14
106	Usefulness of Magnetic Resonance Imaging in the Diagnosis of Juxtaglomerular Cell Tumors: A Report of 10 Cases and Review of the Literature. American Journal of Kidney Diseases, 2019, 73, 566-571.	1.9	13
107	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	2.7	13
108	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12

#	Article	IF	Citations
109	Hereditary angio-oedema: effective treatment with the progestogen-only pill in a young woman. British Journal of Dermatology, 2004, 151, 713-714.	1.5	11
110	MicroRNA-204 Is Necessary for Aldosterone-Stimulated T-Type Calcium Channel Expression in Cardiomyocytes. International Journal of Molecular Sciences, 2018, 19, 2941.	4.1	11
111	Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 898-907.	3.6	11
112	Pheochromocytoma: When to search a germline defect?. Presse Medicale, 2018, 47, e109-e118.	1.9	10
113	Retinoic acid receptor Î± as a novel contributor to adrenal cortex structure and function through interactions with Wnt and Vegfa signalling. Scientific Reports, 2019, 9, 14677.	3.3	10
114	Acute Stress Cardiomyopathy: Heart of pheochromocytoma. Annales D'Endocrinologie, 2021, 82, 201-205.	1.4	10
115	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1301-e1315.	3.6	10
116	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex â€“ a multicenter-study of 3566 Caucasian and Asian subjects. European Journal of Endocrinology, 2022, 187, 361-372.	3.7	9
117	Deciphering the Role of Vasopressin in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3297-3303.	3.6	8
118	Diagnostic criteria for adrenal venous sampling. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 218-224.	2.3	8
119	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2726-2737.	3.6	8
120	Renal Outcome and New-Onset Renal and Extrarenal Dissections in Patients With Nontrauma Renal Artery Dissection Associated With Renal Infarction. Hypertension, 2021, 78, 51-61.	2.7	8
121	Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia. Journal of the American Heart Association, 2021, 10, e018311.	3.7	7
122	Awareness of Individual Cardiovascular Risk Factors and Self-Perception of Cardiovascular Risk in Women. American Journal of the Medical Sciences, 2017, 354, 240-245.	1.1	6
123	Colocalization of Wnt/Î²-Catenin and ACTH Signaling Pathways and Paracrine Regulation in Aldosterone-producing Adenoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 419-434.	3.6	5
124	How to Explore an Endocrine Cause of Hypertension. Journal of Clinical Medicine, 2022, 11, 420.	2.4	5
125	SELECTION OF PATIENTS FOR SURGERY FOR PRIMARY ALDOSTERONISM. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 522-525.	1.9	4
126	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	3.6	4

#	Article	IF	Citations
127	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. Hypertension, 2017, 69, 985-991.	2.7	3
128	Arterial stiffness evaluated by pulse wave velocity is not predictive of the improvement in hypertension after adrenal surgery for primary aldosteronism: A multicentre study from the French European Society of Hypertension Excellence Centres. Archives of Cardiovascular Diseases, 2018, 111, 564-572.	1.6	3
129	Perioperative outcomes of pheochromocytoma/paraganglioma surgery preceded by Takotsubo-like cardiomyopathy. Surgery, 2022, 172, 913-918.	1.9	2
130	[OP.2B.08] ETIOLOGY OF RENAL INFARCTIONS. Journal of Hypertension, 2016, 34, e20-e21.	0.5	1
131	Case of Primary Aldosteronism With Discordant Hormonal and Computed Tomographic Findings. Hypertension, 2017, 69, 529-535.	2.7	1
132	Resistant Hypertension. , 2018, , 398-408.		1
133	Apports de COMETE Ã la gÃ©nÃ©tique du phÃ©ochromocytome. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 105-116.	0.0	1
134	SAT-012 Urinary Aldosterone Assay Using LC-MS/MS Could Improve Primary Aldosteronism Screening. Journal of the Endocrine Society, 2019, 3, .	0.2	1
135	Hypertension With Negative Metaiodobenzylguanidine Scintigraphy. Hypertension, 2022, 79, 474-478.	2.7	1
136	Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword. Journal of Hypertension, 2013, 31, 1948-1951.	0.5	0
137	CO-33: Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma. Annales De Cardiologie Et D'Angeiologie, 2015, 64, S16.	0.6	0
138	CO-14: Assessment of patients attending hypertension consultations at University Hospital Georges Pompidou in the last 15 years. Annales De Cardiologie Et D'Angeiologie, 2015, 64, S8-S9.	0.6	0
139	P3-22: Renal infarction : etiology analysis in a 244 case series. Annales De Cardiologie Et D'Angeiologie, 2015, 64, S30.	0.6	0
140	CO-34: Retinoic acid receptor signaling contributes to adrenal morphology and functional zonation. Annales De Cardiologie Et D'Angeiologie, 2015, 64, S16.	0.6	0
141	[OP.3A.02] RETINOIC ACID RECEPTOR SIGNALING CONTRIBUTES TO ADRENAL CORTEX MORPHOLOGY AND FUNCTIONAL ZONATION. Journal of Hypertension, 2016, 34, e26.	0.5	0
142	[OP.2A.07] TRENDS IN PATIENTS ATTENDING A TERTIARY HYPERTENSION UNIT. Journal of Hypertension, 2016, 34, e17.	0.5	0
143	[OP.3A.06] LONG TERM FOLLOW-UP IN PATIENTS OPERATED ON A PHEOCHROMOCYTOMA OR A PARAGANGLIOMA. Journal of Hypertension, 2016, 34, e28.	0.5	0
144	[OP.LB01.12] CACNA1H MUTATIONS ARE ASSOCIATED WITH YOUNG ONSET AND FAMILIAL FORMS OF PRIMARY ALDOSTERONISM. Journal of Hypertension, 2016, 34, e39.	0.5	0

#	Article	IF	Citations
145	[OP.7D.02] INCREASE IN PLASMA COPEPTIN CONCENTRATION IN PATIENTS WITH CONFIRMED RESISTANT ESSENTIAL HYPERTENSION. Journal of Hypertension, 2016, 34, e94.	0.5	0
146	Pheochromocytoma/Paraganglioma: Management, Genetics, and Follow-up. , 2019, , 469-477.		0
147	Does stenting for atherosclerotic renovascular disease improve blood pressure and kidney function better than medical treatment?. Polish Archives of Internal Medicine, 2009, 119, 612-613.	0.4	0
148	Statut tensionnel, phÃ©notype sÃ©crÃ©toire et potentiel mÃ©tastatique chez les patients porteurs de phÃ©ochromocytome ou de paragangliome : donnÃ©es gÃ©nÃ©tiques et physio-pathologiques rÃ©centes. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 313-319.	0.0	0
149	ArtÃ©riopathie athÃ©romateuse des artÃ¨res rÃ©nales. , 2016, , 221-225.		0